Updates from MariTide & Orforglipron research

MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.

After two months, Novo Nordisk and HIMS part ways

Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.

Preserving muscle: GLP1s with Bimagrumab

We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.

Novo Nordisk patent protections lapse in Canada

Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.

A challenge to Eli Lilly's Tirzepatide patent

Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.

Amylin, with and without GLP1: Eloralinitide

We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.

Ozempic is not likely to directly enlarge the male appendage.

A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.

Eli Lilly's big Summer 2025 update

We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.

Semaglutide vs Tirzepatide (Clinical trial)

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

Roche and Carmot's GLP1 pipeline

We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.

A new risk: Kidney Cancer

New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.

GLP1s vs. Addiction, a quick review

We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.